Identification of protein biomarkers of attenuation and immunogenicity of centrin or p27 gene deleted live vaccine candidates of Leishmania against visceral leishmaniasis

Tandon, Rajendra; Reyaz, Enam; Roshanara, None; Jadhav, Manali; Gandhi, Mayuri N.; Dey, Ranadhir; Salotra, Poonam; Nakhasi, Hira L.; Selvapandiyan, Angamuthu

doi:10.1016/j.parint.2022.102661

Cited by 4 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using this principle, first-, second-, and third-generation antileishmanial vaccines have been developed, yet no patient candidates have had effective results for the transition to clinical trials beyond phase I. As a result, there is currently no licensed vaccine for human VL and CL ( Malvolti et al, 2021 ; Tandon et al, 2023 ). The first-generation prophylactic vaccines for leishmaniasis were shown to be ineffective, despite their ability to induce Th1-type cytokine responses.…”

Section: Introductionmentioning

confidence: 99%

Leishmaniasis: Recent epidemiological studies in the Middle East

et al. 2023

View full text Add to dashboard Cite

Leishmaniasis, one of the most neglected tropical diseases (NTDs), is the third most important vector-borne disease worldwide. This disease has a global impact and severity of the infection and is greatest in the Middle East. The agent of infection is a protozoan parasite of the genus, Leishmania, and is generally transmitted by blood-sucking female sandflies. In humans, there are three clinical forms of infection: (1) cutaneous (CL), (2) mucocutaneous (ML), and (3) visceral leishmaniasis (VL). This review aims to discuss the current epidemiological status of leishmaniasis in Saudi Arabia, Iraq, Syria, and Yemen with a consideration of treatment options. The elevated risk of leishmaniasis is influenced by the transmission of the disease across endemic countries into neighboring non-infected regions.

show abstract

Section: Introductionmentioning

confidence: 99%

Leishmaniasis: Recent epidemiological studies in the Middle East

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The current course of treatment is based on chemotherapy using a small number of drugs. However, these drugs have shown significant drawbacks, e.g., high cost and toxicity, challenging routes of administration, and low efficacy in endemic areas (Baneth & Solano-Gallego, 2022;Ostolin et al, 2022;Tandon et al, 2023;Wu et al, 2020). On the other hand, diagnosing leishmaniasis (VL, CL, and MCL) is challenging due to the wide spectrum of clinical manifestations and parasite diversity.…”

Section: Introductionmentioning

confidence: 99%